Halozyme awards CEO $10M performance-based RSUs tied to stock price targets $115-$170

HALOZYME THERAPEUTICS, INC.

Compensation Committee approved one-time PSU grant for CEO Dr. Helen Torley with $10M target fair value.
Shares vest based on achieving 20-trading-day average stock price of $115 (50%), $130 (100%), $145 (150%), or $170 (200%) over 4-year performance period.
Time-based vesting requires continued employment through fourth anniversary; voluntary resignation/retirement forfeits all performance-vested shares.
Grant intended to retain CEO and incentivize growth and profitability during next stage.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.